Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …

Epidermal growth factor receptor (EGFR), the receptor for members of the epidermal growth
factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related …

Melanoma is considered one of the most aggressive skin cancers. It spreads and
metastasizes quickly and is intrinsically resistant to most conventional chemotherapeutics …

Here in, we report the design, synthesis and in vitro anticancer activity of a novel series of 24
quinoline analogues of substituted amide and sulphonamide derivatives. The anticancer …

Lung cancer, renowned for its fast progression and metastatic potency, is rising to become a
leading cause of death globally. It has been long observed that lung cancer is particularly …

Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase widely expressed in
many cancers such as non-small cell lung cancer (NSCLC), pancreatic cancer, breast …

Resistance is the major cause of treatment failure and disease progression in non-small cell
lung cancer (NSCLC). There is evidence that hypoxia is a key microenvironmental stress …

The current landscape of targeted therapies directed against oncogenic driver alterations in
non–small cell lung cancer (NSCLC) is expanding. Patients with EGFR-mutant NSCLC can …

Simple Summary Non-small cell lung cancer (NSCLC) is the most common cancer in the
world. For common EGFR mutations, treatment is based on different inhibitors. Despite the …

Over the past 2 decades, rapid advances in molecular profiling and the development of
targeted therapies have dramatically improved the clinical course of advanced non-small …